To include your compound in the COVID-19 Resource Center, submit it here.

A very focused $20M start-up

Cancer BioScience Corp., a new company designed to bridge the worlds of pure science and applied medicine, is slated to be launched in October with initial capital of about $20 million from private individuals.

The Boston-based company will combine two newly popular concepts in company development: a disease focus and a "virtual company" structure.

"Cancer BioScience is being built on the model of a company without walls," said co-founder Ralph Ingersoll. "We had in mind the space shuttle program. As such, the Boston office will handle three projects -

Read the full 880 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers